RxDoctor Payments DataLook up a doctor →

Alex Nelson, MD

Interventional Pain Medicine · Murray, UTNPI 1730405408

Payments from drug & device makers

$45,804in general payments, 2019–2025

Across 462 payments — averaging $99.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$30K
  • Medtronic$8K
  • Boston Scientific$3K
  • Relievant Medsystems, Inc.$1K
  • Lundbeck LLC$308
  • Amgen$270
  • plus $3K from 38 others

What the payments were for

  • Consulting fees$2001%
  • Speaking & faculty fees$4,96030%
  • Travel & lodging$3,39420%
  • Food & beverage$8,02748%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,804 in reported general payments places this provider in the 90th percentile of 26 interventional pain medicine providers in Utah.

See all interventional pain medicine providers in Utah

Medicare billing

Part B allowed, 2024
$292,967
Medicare patients
414
Services billed
3,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina18$25,212
Emgality PenGalcanezumab-Gnlm29$20,177
Glatiramer Acetate11$15,266
Oxtellar XrOxcarbazepine15$11,420
Xtampza ErOxycodone Myristate14$5,614
MovantikNaloxegol Oxalate12$5,150
Buprenorphine22$4,917
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen126$4,011
Gabapentin96$1,949
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen114$1,762
Pregabalin44$926
Propranolol Hcl ErPropranolol Hcl25$838
Oxycodone Hcl45$794
Carbidopa-LevodopaCarbidopa/Levodopa35$759
Duloxetine Hcl32$759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$29,620$25,21218 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$154$11,42015 claims
Collegium Pharmaceutical, Inc.Xtampza Er$237$5,61414 claims
Redhill Biopharma Inc.Movantik$16$5,15012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 26 interventional pain medicine providers in Utah.

Other interventional pain medicine in Murray

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →